Evidence map›Paper›PMID 40272170›Full record

ArticleMicrobiology spectrum2025

Multi-year comparison of VITEK MS performance for identification of rarely encountered pathogenic gram-positive organisms (GPOs) in a large integrated Canadian healthcare region.

D L Church, T Griener, D Gregson

Abstract readComparative Study
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

D L ChurchDepartment of Pathology and Laboratory Medicine, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0009-0008-9941-9050
T GrienerDepartment of Pathology and Laboratory Medicine, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada.
D GregsonDepartment of Pathology and Laboratory Medicine, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This multi-year study (2014-2019) compared identification of rare and unusual gram-positive organisms (GPOs) by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (VITEK MS; bioMérieux, Laval, Quebec) to 16S rRNA gene sequencing (16S) according to our laboratory routine workflow. 16S is done if initial MALDI-TOF MS results are discordant or wrong, or there are no results. GPO isolates were first analyzed by standard phenotypic methods and MALDI-TOF MS using direct deposit with full formic acid extraction; MALDI-TOF was repeated if no result occurred. Medically approved 16S analyses were done using fast protocols. Isolate sequences were analyzed using the Integrated Database Network System bacterial database (SmartGene, Lausanne, Switzerland). 655 GPO isolates were recovered from 648 specimens; >1 isolate was recovered from 7 (1%). A total of 451 (68.9%) aerobic gram-positive bacilli (GPBs) and 204 (31.1%) aerobic gram-positive cocci (GPCs) were mainly recovered from bloodstream infections (35%), sterile fluids and deep tissues (35%), and abscesses/deep wounds (17%). Accurate genus vs species identities were obtained for 59% and 49.4% GPB, and 81% and 53.9% GPC, respectively. Wrong or no results were obtained for 9% and 31% of GPB and 7% and 12% of GPC; 15% of GPBs and 5.3% of GPC identification errors occurred due to absence from the instrument's database. VITEK MS performance remained stable for GPB and GPC isolates due to few species additions to the database. VITEK MS databases need to be continually updated to include an increasing number of rare and unusual GPOs causing invasive human infections. 16S remains important for identification of GPOs where MALDI-TOF fails.IMPORTANCEMALDI-TOF MS has transformed the identification of commonly encountered GPOs in the clinical laboratory, but rare and unusual bacteria continue to challenge the technology. This study verified the performance of VITEK MS for identification of a broad range of rare and unusual clinical GPO isolates by our large reference laboratory workflow over a multi-year period. Although most GPOs were accurately identified by MALDI-TOF MS, a small number of common GPC isolates (6.3%) (i.e.,

Indexed as

Bacterial Typing TechniquesGram-Positive BacteriaGram-Positive Bacterial InfectionsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationCanadaDNA, BacterialHumansRNA, Ribosomal, 16SDNA, BacterialRNA, Ribosomal, 16Sgram-positive bacteriaidentificationMALDI-TOFVITEK MS

Identifiers

PMID40272170
PMCPMC12131779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.